Neuroone Medical Technologies (NMTC) Amortization of Deferred Charges (2016 - 2024)

Neuroone Medical Technologies (NMTC) posted Amortization of Deferred Charges of $192647.0 for Q4 2024, down 63.97% on a QoQ basis from $534661.0 in Q3 2018.

Neuroone Medical Technologies (NMTC) Amortization of Deferred Charges (2016 - 2024) Analysis & Trends

Neuroone Medical Technologies' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $192647.0 for Q4 2024.

  • Quarterly Amortization of Deferred Charges changed N/A year-over-year to $192647.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $192647.0 (changed N/A YoY) and the FY2025 annual result came in at $192647.0, up 90.12% from the prior year.
  • Amortization of Deferred Charges was $192647.0 for Q4 2024 at Neuroone Medical Technologies, down from $534661.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $192647.0 in Q4 2024 and bottomed at $192647.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn -
10 Neuroone Medical Technologies 7.99 Mn 5.19 Mn 990,264.00

Historic Data

Download Data
DateValue
Dec 31, 2024 192,647.00
Dec 31, 2024 192,647.00
Sep 30, 2018 534,661.00
Sep 30, 2018 534,661.00
Jun 30, 2018 675,632.00
Jun 30, 2018 675,632.00
Mar 31, 2018 437,524.00
Mar 31, 2018 437,524.00
Sep 30, 2017 284,637.00
Sep 30, 2017 284,637.00
Dec 31, 2016 27,555.00
Dec 31, 2016 27,555.00